Related Experiment Videos
Climate risk perception and pharmaceutical supply chain resilience in China
Shipeng Wang1, Han Zhuo2, Hui Zhang3
1School of Business, Shandong Normal University, Jinan, Shandong, China.
Abstract:
Climate risk shocks to the global supply chain are becoming more severe, and the pharmaceutical industry is especially vulnerable, given the high stakes of patient safety, cold-chain constraints, geographic concentration of active pharmaceutical ingredients, and stringency of quality regulation. Using panel data on pharmaceutical manufacturers listed in the A-share from 2003 to 2024, we construct a climate risk perception indicator based on the textual analysis of annual reports and examine its impact on the supply chain resilience of firms and the mechanisms involved. Our findings show that the heightened climate risk perception significantly enhances supply chain resilience. This relationship is robust to alternative dependent and independent variables, alternative specifications of fixed effects, and different trimming ranges. Three mechanisms drive the effects: (i) promoting green innovation, (ii) deepening supplier relationships, and (iii) diversifying customer concentration. The heterogeneity analyses suggest that the effects are stronger for state-owned enterprises, smaller firms, and firms with higher managerial risk aversion. This study connects climate risk perception and supply chain resilience in a regulated pharma context, offering new theory and empirical evidence for resilience in relationship-driven supply chains.
Related Concept Videos
Pharmaceutical Poisoning: Potential Scenarios
Drug Control Governance: Regulatory Bodies and Their Impact
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Modified-Release Drug Delivery Systems: Influencing Factors
Drug Product Stability